Rosuvastatin
Crestor
Rosuvastatin (Crestor) is a longevity & bioregulators research compound. HMG-CoA reductase inhibitor — cuts hepatic cholesterol synthesis, which upregulates LDL receptors and pulls ApoB particles out of circulation.
Rosuvastatin quick facts
| Reported research dose | 5–20mg daily |
| Route | Oral |
| Frequency | 1x |
| Half-life | ~19 hours, and it's hydrophilic, so less muscle tissue penetration than the lipophilic statins. |
| Forms | Oral |
| Evidence level | JUPITER and a very large outcome-trial base |
Oral AAS wreck HDL and drive ApoB up; this is the most-used correction. Rosuvastatin is often better tolerated than atorvastatin for muscle complaints because it's hydrophilic. Track ApoB, not LDL-C — they disagree more than people expect. Check ALT/AST at baseline.
How Rosuvastatin works
HMG-CoA reductase inhibitor — cuts hepatic cholesterol synthesis, which upregulates LDL receptors and pulls ApoB particles out of circulation.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Rosuvastatin
Buy Rosuvastatin at AlgoRx →The evidence for Rosuvastatin
Graded by what exists behind each claim.
✅ Clinically validated
- Approved with extensive trial data. JUPITER (17,802 participants) is the landmark: in people with normal LDL but elevated hsCRP, it reduced major cardiovascular events by 44% — establishing that inflammation identifies risk that cholesterol alone misses.
- JUPITER also found a modest increase in new-onset diabetes, which is a genuine class effect and is consistently reported. The absolute cardiovascular benefit exceeded it in that population, but it is a real trade rather than a footnote.
📊 Correlative data
- Very wide prescribing. Muscle symptoms are the dominant real-world complaint and the dominant reason people stop — and the n-of-1 rechallenge literature (SAMSON and similar) found most attributed symptoms recurred on placebo, which is a real and uncomfortable finding rather than a dismissal.
- It is more hydrophilic than most statins, which reduces muscle tissue penetration and is the mechanistic argument for switching to it when another statin causes symptoms.
🧪 Theoretical / extrapolated
- Inhibits HMG-CoA reductase, the rate-limiting step in hepatic cholesterol synthesis. Falling intracellular cholesterol upregulates LDL receptors, which pull LDL out of circulation — the receptor upregulation, not the synthesis block, is what lowers blood LDL.
- The same pathway produces CoQ10, which is the mechanistic basis for the CoQ10-for-statin-myalgia idea — plausible, and not well supported by trials.
- It also lowers hsCRP independently of LDL, which is the pleiotropic effect JUPITER was built around.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Rosuvastatin actually does
Every statin inhibits the same enzyme. What separates them is how they get into the liver, and rosuvastatin is the clearest case in the class because it cannot get in on its own.
The enzyme, and the two-step consequence. HMG-CoA reductase converts 3-hydroxy-3-methylglutaryl-CoA to mevalonate, the committed and rate-limiting step of cholesterol synthesis. Statins are competitive inhibitors that occupy the HMG-CoA binding site. But lowering synthesis is only half the mechanism, and it is the smaller half. Falling intracellular sterol activates SREBP-2, which is cleaved and travels to the nucleus to transcribe the LDL receptor. More LDL receptors on the hepatocyte surface means more clearance of circulating LDL particles. The measured drop in LDL is mostly receptor-mediated clearance, not reduced production — which is why the effect requires a working liver and why it plateaus.
The property that makes rosuvastatin different: it is hydrophilic. Lipophilic statins diffuse passively into any cell, including myocytes. Rosuvastatin is relatively hydrophilic and does not, so it must be actively transported. The transporter is OATP1B1, encoded by SLCO1B1, on the sinusoidal membrane of the hepatocyte. That makes hepatoselectivity a transport property rather than a chemical accident, and it is the mechanistic basis of the card's note that a hydrophilic statin penetrates muscle less.
And it turns a transporter gene into a dosing variable. Reduced-function SLCO1B1 variants slow hepatic uptake, so drug that should have been extracted on first pass stays in the systemic circulation and reaches tissues the design was trying to spare. The Clinical Pharmacogenetics Implementation Consortium has published a guideline covering SLCO1B1, ABCG2 and CYP2C9 genotypes and statin-associated musculoskeletal symptoms Cooper-DeHoff 2022. ABCG2 matters specifically for rosuvastatin because it is the efflux pump that puts the drug back out into bile and gut lumen; a reduced-function ABCG2 raises exposure the same way a reduced-function uptake transporter does, from the other direction. A case report describes rosuvastatin-induced rhabdomyolysis in a patient of African ancestry carrying SLCO1B1 variants Medwid 2024, and a gene risk score built from SLCO1B1 missense variants is associated with earlier-onset statin intolerance Bigossi 2023.
The pleiotropic argument, stated as what it is. Blocking mevalonate does not only stop cholesterol; mevalonate is also the precursor of farnesyl and geranylgeranyl groups that anchor small GTPases such as Rho and Rac to membranes. Less prenylation means less Rho signaling, which raises endothelial nitric oxide synthase expression and lowers NADPH-oxidase-driven oxidant production. That is the molecular basis for the anti-inflammatory effects attributed to statins German 2023 — a real biochemical pathway, and still an argument about how much of the clinical benefit it accounts for.
Cell, rodent, human — and where it stops
Step one, biochemistry: settled. Enzyme inhibition, SREBP-2 activation and LDL receptor upregulation are textbook, and the prenylation branch is characterized German 2023.
Step two, humans, and the pharmacogenetics reached guideline strength. CPIC guidelines are not reviews; they are prescribing recommendations issued only when the evidence supports action. That SLCO1B1, ABCG2 and CYP2C9 reached that bar for statin-associated musculoskeletal symptoms Cooper-DeHoff 2022 means the transporter argument above is not theoretical — it is the basis of a published, actionable dosing document.
Step three, the individual end of the same evidence. A gene risk score using missense SLCO1B1 variants predicts earlier onset of statin intolerance Bigossi 2023, and the extreme of the distribution has been documented as rhabdomyolysis in a genotyped patient Medwid 2024. Population guideline, risk score, case report: the same mechanism at three different resolutions, which is what a real translation chain looks like.
Step four, the inflammation endpoint, which is contested and worth stating as contested. Whether hs-CRP should be measured at all in atherosclerotic cardiovascular disease is the subject of a 2025 appraisal titled, in as many words, To Measure or Not to Measure? Mehta 2025. This site takes the side that says measure it, for one specific reason: it is the only widely available number that distinguishes a person whose residual risk is lipid from a person whose residual risk is inflammatory, and those two people need different next steps.
Step five, the drug-drug arithmetic. Rosuvastatin is a standard probe substrate when a new agent is tested for transporter interactions — a GLP-1 analog's effect on rosuvastatin and digoxin pharmacokinetics has been studied in exactly that role Li 2026. Being the probe is informative in itself: it means regulators treat rosuvastatin exposure as sensitive enough to reveal a transporter effect that other drugs would hide.
Where the chain breaks. (1) The CPIC guideline governs musculoskeletal symptoms; it is not a statement about cardiovascular benefit, and genotype-guided dosing has not been shown in a randomized trial to improve outcomes. (2) The pleiotropic mechanisms German 2023 are established biochemically and their clinical share is unknown, because no trial can lower LDL by a statin without also inhibiting prenylation. (3) Muscle symptom reporting is heavily affected by expectation, and n-of-1 rechallenge trials in the wider statin literature repeatedly find a large nocebo component. (4) Coenzyme Q10 supplementation for statin myopathy has been meta-analyzed with mixed conclusions Wei 2022 Fogacci 2024, and this page does not treat it as settled.
What would have to be true, and how you would know it was not
Three predictions. The first is the drug working, the second is the one almost everybody measures wrongly, and the third is the falsification test for a symptom.
1. If the LDL receptor is being upregulated, the particle count falls and it falls fast. A lipid panel plus ApoB at baseline and at 6 to 8 weeks — not 12, because the effect is essentially complete once the receptor pool has turned over. ApoB is the better number than LDL cholesterol because it counts particles rather than the cholesterol carried inside them, and the two disagree most in exactly the people who most need the answer: those with high triglycerides and small dense LDL. Lp(a) is worth measuring once in a lifetime here, because statins do not lower it and a high Lp(a) explains residual risk that looks like treatment failure.
2. The prediction that separates lipid risk from inflammatory risk. hs-CRP at baseline and at 8 weeks. If LDL and ApoB fall and hs-CRP does not, the residual risk is not being addressed by this drug and the argument in Mehta 2025 becomes personal rather than academic. Measure hs-CRP away from any acute illness — a cold, a dental infection or a hard training session will produce a number that means nothing about atherosclerosis, and that is the single commonest way this test is misread.
3. Muscle symptoms have a falsification test and it is a planned rechallenge. The mechanism predicts a specific pattern: symptoms that begin after starting, are dose-related, resolve within a few weeks of stopping, and return on rechallenge. A CMP for creatinine and liver enzymes belongs at baseline and 12 weeks. Dark urine with severe muscle pain is a different event entirely — that is the rhabdomyolysis presentation Medwid 2024, it is an emergency, and it is not the aching described above. If symptoms are real and reproducible, SLCO1B1 and ABCG2 genotyping has an actionable guideline behind it Cooper-DeHoff 2022, which very few pharmacogenetic tests do.
What nobody has tested yet
Four experiments nobody has finished.
Nobody has run a randomized trial of genotype-guided statin prescribing with outcomes. The CPIC guideline exists Cooper-DeHoff 2022 and the risk score exists Bigossi 2023, but whether genotyping before the first prescription reduces discontinuation and therefore improves cardiovascular outcomes has not been tested. Adherence, not potency, is where most statin benefit is lost, which makes this the highest-value unrun trial on this page.
Nobody has separated the pleiotropic effect from the LDL effect in humans. Every statin does both German 2023. The experiment that separates them is a comparison against a non-statin LDL-lowering agent matched for ApoB reduction, with inflammatory and endothelial endpoints — ezetimibe combination data speaks to the LDL side of that question Oyama 2021 but was not designed to answer the mechanistic one.
Nobody has settled coenzyme Q10. Statins reduce mevalonate and coenzyme Q10 is made from a mevalonate-derived precursor, so the hypothesis is mechanistically coherent. The meta-analyses disagree Wei 2022 Fogacci 2024. The trial that would settle it — genotype-confirmed statin-intolerant participants, muscle coenzyme Q10 content measured rather than assumed, blinded rechallenge — has not been run.
Nobody has tested intermittent dosing properly against the genotype. Rosuvastatin's ~19-hour half-life makes alternate-day or thrice-weekly dosing pharmacologically plausible, and it is used in practice for people who cannot tolerate daily therapy. Whether it delivers the same ApoB reduction in reduced-function SLCO1B1 carriers specifically — the group most likely to need it — is unstudied.
Rosuvastatin — its own safety story, not its class's
Rosuvastatin is a prescription medicine taken by tens of millions of people, so the risks are unusually well quantified and the class block above is too vague to be useful.
Muscle symptoms are the reason people stop, and they exist on a spectrum that gets collapsed into one word. At one end, myalgia without enzyme change, common, reversible, and with a large nocebo component in blinded rechallenge. At the other, rhabdomyolysis: severe pain, weakness, dark urine, kidney injury, rare, and a medical emergency — documented for rosuvastatin in a genotyped patient Medwid 2024. Calling both of these statin muscle problems is what makes the first one frightening and the second one easy to miss.
The interactions that matter are transporter interactions, not CYP interactions, and that is genuinely different from most statins. Rosuvastatin undergoes little cytochrome metabolism, so the classic CYP3A4 list matters less. What matters is anything inhibiting OATP1B1 or ABCG2 Cooper-DeHoff 2022 — several antivirals, cyclosporine, gemfibrozil, and some antibiotics. Anyone reasoning from grapefruit and CYP3A4 is reasoning about a different statin.
Ancestry changes the starting dose and the reason is genetic. Reduced-function transporter variant frequencies differ between populations, which is why rosuvastatin labeling has long carried a lower starting dose for patients of Asian ancestry, and why the case report of rhabdomyolysis in a patient of African ancestry was published as a genotype finding rather than an anecdote Medwid 2024.
The glucose signal is real and small. Statins produce a small increase in new-onset diabetes, concentrated in people already close to the threshold. It is a reason to check HbA1c, not a reason to avoid a drug with an outcome benefit — but a person should be told rather than discover it.
Liver enzymes: monitor, do not panic. Transient transaminase rises are common and clinically significant liver injury is rare. A CMP at baseline and at 12 weeks is the sensible instrument, and a mild isolated rise is not by itself a reason to stop.
What this page will not do. Recommend a dose, or tell anyone to stop a statin. This is a drug whose benefit is measured in cardiovascular events over years and whose commonest harm is reversible; the decision belongs with the person who can see the whole risk picture.
Sources read for this page
- Cooper-DeHoff RM, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics 2022 · PMID 35152405
- Medwid S, et al. SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin-induced rhabdomyolysis: A case report. British Journal of Clinical Pharmacology 2024 · PMID 39511784
- Bigossi M, et al. A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance. European Heart Journal - Cardiovascular Pharmacotherapy 2023 · PMID 37253618
- German CA, et al. Understanding the molecular mechanisms of statin pleiotropic effects. Archives of Toxicology 2023 · PMID 37084080
- Mehta A, et al. High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?. US Cardiology Review 2025 · PMID 40171210
Rosuvastatin — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- Blocking HMG-CoA reductase cuts hepatic cholesterol synthesis, which makes the liver upregulate LDL receptors and pull ApoB particles out of circulation. Everything predictable follows from where that enzyme sits: it is upstream of the whole mevalonate pathway, so the same block reduces ubiquinone (CoQ10) and prenylated protein synthesis as well as cholesterol.
- That shared pathway is the mechanistic basis for the muscle complaints — and it is worth being precise, because the muscle story is the most misreported thing in this class. See `observed`.
What has actually been reported
- Muscle symptoms are common in practice and largely not drug-attributable in blinded conditions. Statin n-of-1 trials and blinded rechallenge studies have repeatedly found that most people who report symptoms on a statin report them equally on placebo. That does not mean the symptoms are imagined; it means the statin is usually not the cause, and a blinded rechallenge is the way to find out for your own case.
- Genuine rhabdomyolysis is rare and is dose- and interaction-driven — it is the reason the interaction list below matters more than the symptom list.
- A small increase in new-onset type 2 diabetes, concentrated in people already close to the threshold. The cardiovascular benefit outweighs it in the populations studied, and it is a reason to watch HbA1c rather than a reason to stop.
- Transaminase rises are usually mild and transient; clinically meaningful liver injury is rare.
How to reduce the risk
Same mechanism as the prediction.
- Draw a baseline ApoB, ALT and CK before the first dose. Without the CK baseline, every future muscle ache is an argument you cannot settle.
- If muscle symptoms appear, stop, wait for them to clear, and rechallenge rather than switching drugs blind. Most people rechallenge uneventfully, and the ones who do not have learned something real.
- Watch HbA1c if you are already insulin resistant — the diabetes signal concentrates there and it is the one thing you will not feel.
- Alternate-day dosing of a long-half-life statin is a legitimate option for tolerability and keeps most of the ApoB effect.
What it does to your bloodwork
A fact about the assay.
- ApoB is the marker to judge this on, not LDL-C. LDL-C underestimates particle burden when triglycerides are high, which is exactly the group most likely to be on treatment.
- Baseline and follow-up ALT/AST, and HbA1c given the diabetes signal.
- Creatine kinase is worth having as a baseline so that a later muscle complaint can be measured against something instead of guessed at.
- Plasma CoQ10 falls partly because its lipoprotein carriers fall — a lower number on a statin is not by itself evidence of tissue depletion. See the CoQ10 marker page for why that measurement is harder than it looks.
What it overlaps with
- The dangerous combinations are pharmacokinetic, not mechanistic: ciclosporin, gemfibrozil, and some antivirals and antifungals raise statin exposure substantially. Rosuvastatin plus ciclosporin is a documented several-fold exposure rise.
- Ezetimibe stacks rather than overlaps — different mechanism, additive ApoB reduction, no shared toxicity.
Don't run this if
- Pregnancy, breastfeeding or trying to conceive.
- Active liver disease with unexplained persistent transaminase elevation.
- A previous genuine statin-associated rhabdomyolysis.
The honest unknown
- Rosuvastatin is largely renally cleared and is not a strong CYP3A4 substrate, which is why it interacts differently from simvastatin — but the long-term outcome data in healthy, normolipidemic people taking it for longevity rather than for risk does not exist. The trials enrolled people with elevated risk. Whether the same risk-benefit holds at a low baseline ApoB is an extrapolation.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Rosuvastatin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Rosuvastatin moves on your bloodwork
Expected direction, not a measured one.
- ApoB (Apolipoprotein B) — ↓ expected to fall
ApoB is the number that matters here, not LDL-C. ApoB counts the actual atherogenic particles; LDL-C estimates the cholesterol inside them, and the two diverge in exactly the people who most need treating — high triglycerides, metabolic syndrome, small dense LDL.
What to do: Baseline and again at 8–12 weeks. If your lab will only run a standard lipid panel, ask for ApoB specifically. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Falling total and LDL cholesterol is the drug working. Note that LDL-C is usually CALCULATED rather than measured, and the calculation becomes unreliable when triglycerides are high.
What to do: Fast beforehand if triglycerides are part of what you are tracking. - Lipoprotein(a) — Lp(a) — ◆ worth watching
Lipoprotein(a) is largely genetic and statins do not lower it — some data suggests they nudge it slightly up. It is worth knowing once in your life because it changes how aggressively the rest is worth treating.
What to do: Test it once. If it is normal you never need it again; if it is high, that is a real finding about your risk that no lifestyle change will move. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver enzymes can rise on a statin. Clinically meaningful hepatotoxicity is rare, and routine monitoring was dropped from most guidelines — but a baseline is still worth having.
What to do: Baseline, then only if symptoms appear. - Coenzyme Q10 — ↓ expected to fall
Statins inhibit the same pathway that makes CoQ10, so a fall is the predicted mechanistic consequence. Whether that causes the muscle symptoms people attribute to it is genuinely unsettled.
What to do: Worth testing only if you have muscle symptoms — otherwise it is a number without a decision attached.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Rosuvastatin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Rosuvastatin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Rosuvastatin — frequently asked questions
What is Rosuvastatin?
Rosuvastatin (Crestor) is a longevity & bioregulators research compound. HMG-CoA reductase inhibitor — cuts hepatic cholesterol synthesis, which upregulates LDL receptors and pulls ApoB particles out of circulation.
Is the full Rosuvastatin protocol on this page?
The reported research dose is on this page, along with how Rosuvastatin works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Rosuvastatin?
Rosuvastatin has an approximate half-life of ~19 hours, and it's hydrophilic, so less muscle tissue penetration than the lipophilic statins., which is part of what determines how often it's dosed.
What's the evidence behind Rosuvastatin?
Current evidence level: JUPITER and a very large outcome-trial base. Rosuvastatin is offered for research purposes only and is not an approved medicine.
Rosuvastatin inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Rosuvastatin is used for
Rosuvastatin appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Rosuvastatin is the arm with mortality data of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.